All News
Effective Treatments for Rheumatoid Arthritis ILD
The American College of Rheumatology guidelines for the diagnosis and management of interstitial lung disease, which includes rheumatoid arthritis interstitial lung disease (RA-ILD), has been one of the most controversial topics in the runup to ACR Convergence.
Read Article
ARTIC REWIND RCT 3 yrs csDMARD withdrawal
38% 3yrs csDMARDs free remission vs. 80% stable dose gpe
75% recovery after restart
Rx progression 19% in half dose gpe
More use bioDMARDs (18%) & GCs (50%) withdraw gpe
Trends towards lower infections
@RheumNow #ACR23 #ACRBest https://t.co/jhOINV7LLS
Aurelie Najm ( View Tweet)
#CAR T cells #ACR23
🔥Back to back Sessions on one of the most avidly researched area in Rheum!
💡Check out these slides to understand:
☣️Toxicities and Limitations of CAR T therapy
🆕 Novel CAR designs
⚡️CAR cell sources
❓Research Questions to ponder!
#ACRambassador https://t.co/6sOn4rjqY3
debaditya_roy ( View Tweet)
Toxicities and limitations of CAR therapy:
the other side of its incredibly exciting, boundless potential
@Michel_Sadelain @MSKCancerCenter #ACR23 @RheumNow https://t.co/L1UIqqlOdC
David Liew drdavidliew ( View Tweet)
Dr. Sadelain gives a tour-de-force CAR-T overview for the future. Questions around programming antigen sensitivity and the life span of therapy are just the tip of the iceberg. #ACR23 @RheumNow https://t.co/oLog0SiQoE
Dr. Rachel Tate ( View Tweet)
Tapering ABA vs. stable dose ABA in RA
No diff in DAS28 remission at 2 years
But…
Only in patients receiving concomitant MTX
Those tapering ABA mono also experience higher functional important
Of note: not an RCT
@RheumNow #ACR23 ABST2542 https://t.co/yycCDTnRiF
Aurelie Najm ( View Tweet)
How does CAR-T work and how many do we have? Dr. Sadelain details the history, manufacturing, and 6 currently FDA-approved CAR-T products. #ACR23 @RheumNow https://t.co/a4jGfhT8EU
Dr. Rachel Tate ( View Tweet)
Review of the limitations and possible toxicities with CAR-T treatment. ICANs and CRS, while treatable, are very important to educate and understand. This is part of the intersection of heme/onc and rheum. https://t.co/itbwLdHuqf
Dr. Rachel Tate ( View Tweet)
A#2545 IV SEC for SpA #ACR23 @Rheumow
Approved by FDA, though diff dose
Who: Medicare/cost/QoL benefit for IV or obese (wt based dose)
W16: 41% ASAS40 v 23% PBO
W16, PBO switched to SEC. Efficacy W52 (SEC 67%, PBO/Sec 75%)
SAE 6%, discontinuation 3.5%
#ACRBest https://t.co/ruW0ys49gk
Eric Dein ( View Tweet)
Intriguing data on #GCA treated with tocilizumab
#aneurysm still occurs
#vasculitis https://t.co/6cPlFRReLJ
KenWarringtonMD MdWarrington ( View Tweet)
Nepal et al. No increased risk of GI perforation for tocilizumab in GCA HR 1.05 . Diverticulitis (RR 3.51), IV methylprednisolone (RR 5.41) risk factors. This fits with my priors, steroids are a bigger risk than tocilizumab. Abstr#2560 #ACR23 @RheumNow https://t.co/BAmBQA0kEP https://t.co/zRjmDIkOHp
Richard Conway ( View Tweet)
Is rituximab still a problem with COVID - esp if our patients have been vaccinated pre-ritux?
Antibody titres better when not getting regular ritux around boosters
Maybe boosters 9mo (or so) gap after ritux helps immunogenicity
@TroldborgAnne et al #ACR23 ABST2511 @RheumNow https://t.co/dE0uC6B9hx
David Liew drdavidliew ( View Tweet)
What do we know about IL1 drugs in #OA only a small few stidies prior to CANTOS .
COLCHCINE didnt seem to work
LoDoCO2 post hoc analysis may work? @RheumNow #ACR23 https://t.co/h4oVRppI5S
Bella Mehta bella_mehta ( View Tweet)
APTURA 1 study of tocilizumab biosimilar. Not surprisingly no difference. I'm excited about this product. Hopefully be the end to our tocilizumab supply issues and significant societal savings Abstr#0445 #ACR23 @RheumNow https://t.co/qvP7LCeAkm https://t.co/Zb1FUAlXlz
Richard Conway ( View Tweet)
TM84 #ACR23 @RheumNow
49F MS on RTX, severe arthralgias/wt loss, BMI 18. Spontaneous peritonitis, aseptic discitis/osteo, distal radius lucency, hyperammonemia, hypogammaglobulinemia w 1 yr arthritis
Dx: Mycoplasma: ureaplasma urealyticam on culture, PCR improved https://t.co/jM0sARLZS7
Eric Dein ( View Tweet)
Retrospective database study from Japan of PsA pts:
At 12/24 mos ffg tx initiation, 37.5%/49% of pts discontinued index bDMARD while 22.2%/31.2% switched tx.
Dc rates lowest for risankizumab
🤔Reasons for switching/discontinuation not mentioned.
#ACR23 ABST2246 @RheumNow https://t.co/6dhKZmp1wE
sheila ( View Tweet)
Later today at #ACR23 at 4pm
See Ab#2545 on IV secukinumab for AxSpA
Read about it now on @RheumNow:
https://t.co/s9IinpVxgR
Eric Dein ( View Tweet)
The Fallacy of Biologic Treatment to Prevent RA
It is time to stop fooling ourselves that we can prevent RA with our existing biologic agents. #ACR23
https://t.co/qHMW4HGkk2 https://t.co/l2Tn7hGtY3
Dr. John Cush RheumNow ( View Tweet)
Gender differences in switching biologics in PsA pts
Women had higher biologic switch rates, mainly due to lack of efficacy
Other gender specific factors include gestational reasons and different sociodemographic features
@RheumNow #ACR23 Abs#2247 https://t.co/mLm183fCBw
Robert B Chao, MD ( View Tweet)